Table 2.
Baseline characteristics of the sample.
| Variable | Mean | |
|---|---|---|
| Age (mean, ±SD), years | 53.7 ± 14.6 years | |
| BMI (mean, ±SD), kg/m2 | 26.2 ± 4.90 kg/m2 | |
| Male sex (n, %) | 1749 (48.1%) | |
| Charlson Comorbidity Index (median, IQR) | 1 [2]; range: 0–10 | |
| COVID-19 signs and symptoms (median, IQR) | 7 [7]; range: 0–22 | |
Charlson Comorbidity Index (n, %)
|
|
|
Post-COVID-19 syndrome (n, %)
|
|
|
| Post-COVID-19 signs and symptoms (median, IQR) | 3 [4]; range: 0–22 | |
| COVID-19 and post-COVID-19 signs and symptoms (*) | ||
| COVID-19 | post-COVID-19 | |
| Fever (n, %) | 2718 (74.8%) | 116 (3.2%) |
| Fatigue (n, %) | 2792 (76.8%) | 2354 (64.7%) |
| Cough (n, %) | 2025 (55.7%) | 476 (13.1%) |
| Diarrhea (n, %) | 867 (23.8%) | 281 (7.7%) |
| Headache (n, %) | 1726 (47.5%) | 747 (20.5%) |
| Anosmia (n, %) | 1439 (39.6%) | 547 (15.0%) |
| Dysgeusia (n, %) | 1444 (39.7%) | 468 (12.9%) |
| Red eyes (n, %) | 613 (16.9%) | 230 (6.3%) |
| Low or blurred vision (n, %) | 566 (15.6%) | 598 (16.4%) |
| Syncope (n, %) | 220 (6.1%) | 39 (1.1%) |
| Vertigo (n, %) | 758 (20.8%) | 428 (11.8%) |
| Joint pain (n, %) | 1859 (51.1%) | 1071 (29.4%) |
| Skin lesions (n, %) | 320 (8.8%) | 244 (6.7%) |
| Sicca syndrome (n, %) | 639 (17.6%) | 347 (9.5%) |
| Raynaud’s phenomenon (n, %) | 65 (1.8%) | 54 (1.5%) |
| Myalgia (n, %) | 1963 (54.0%) | 1043 (28.7%) |
| Dyspnea (n, %) | 2118 (58.3%) | 1904 (52.3%) |
| Chest Pain (n, %) | 1168 (32.1%) | 594 (16.3%) |
| Sore throat (n, %) | 1075 (29.6%) | 200 (5.5%) |
| Sputum (n, %) | 592 (16.3%) | 218 (6.0%) |
| Rhinitis (n, %) | 952 (26.2%) | 263 (7.2%) |
| Lack of appetite (n, %) | 1238 (34.0%) | 240 (6.6%) |
| Tinnitus (n, %) | 198 (5.4%) | 175 (4.8%) |
| Heartburn (n, %) | 271 (7.4%) | 281 (7.7%) |
| Palpitations (n, %) | 473 (13.0%) | 369 (10.1%) |
| Sleep disturbances (n, %) | 506 (13.9%) | 502 (13.8%) |
| Brain fog and cognitive disturbances (n, %) | 447 (12.3%) | 726 (20.0%) |
| Tingling (n, %) | 277 (7.6%) | 330 (9.1%) |
Legend: BMI = body mass index; IQR = interquartile range; SD = standard deviation; (*) some patients’ signs or symptoms were dropped at the end of follow-up since an organic cause emerged during the multidisciplinary assessment; in other subjects, there were missing cases: we report the percentage of the positive patients in the cohort excluding the missing/dropped cases.